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BHD, TP53, and HNF1b on chromosome 17 were studied in 92 cases of renal cell carcinoma (46 chromophobe, 19 clear cell, 18
oncocytoma, and nine papillary). Six, thirteen, and zero cases had, respectively BHD, TP53, and HNF1b mutations, (84% mutations
involved chromophobe), suggesting a role for BHD and TP53 in chromophobe subtype.
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Renal cell carcinoma (RCC) is mainly comprised of clear cell,
papillary, and chromophobe subtypes. The study of hereditary
kidney cancer syndromes has led to the identification of kidney
cancer-related genes that are also involved in sporadic RCC.
Recently, germline BHD mutations were found in patients with
Birt–Hogg–Dube ´ (BHD) syndrome (Nickerson et al, 2002), and a
diverse spectrum of renal tumours have been described with
somatic inactivation of BHD reported in BHD-related renal
tumours (Khoo et al, 2002; Schmidt et al, 2005; Vocke et al,
2005). BHD promoter methylation has been reported in a subset of
sporadic clear cell and chromophobe RCC, but somatic mutation
of BHD in sporadic cases is rare (da Silva et al, 2003; Khoo et al,
2003). BHD is located at 17p11.2, and LOH has been detected in all
RCC subtypes (Khoo et al, 2003; Vocke et al, 2005). The TP53 gene
is located at 17p13.1 near BHD. A study has reported 30% of
somatic missense mutations of TP53 in chromophobe with LOH of
chromosome 17p, suggesting that TP53 plays a role in this subtype
(Contractor et al, 1997). The HNF1b gene (hepatocyte nuclear
factor), which was found mutated in patients with maturity-onset
diabetes of the young (MODY5), is located at 17q12 (Horikawa
et al, 1997). Biallelic inactivation of this gene has been reported in
two of 12 patients with chromophobe RCC; both patients have
germline HNF1b mutations, and their tumours showed LOH,
suggesting inactivation through the classic two-hit hypothesis
(Rebouissou et al, 2005).
Multiple losses of whole chromosomes were frequently found in
chromophobe RCC, especially in chromosome 17 (Speicher et al,
1994). We hypothesised that the lost chromosomal regions may
harbour chromophobe RCC-specific tumour suppressor genes,
and their inactivation contributes to the tumorigenesis. Here, we
focused on three cancer-related genes located at chromosome 17,
BHD, TP53, and HNF1b, and examined their involvement in
chromophobe RCC by studying 46 cases and compared with 19
clear cell, 18 oncocytoma, and nine papillary subtypes. We
screened these tumours for mutations, evaluated the BHD
promoter methylation status, and estimated the allelic frequencies
of polymorphisms in these genes.
MATERIALS AND METHODS
Tissue samples and DNA extraction
Ninety-two frozen sporadic renal tumour samples were collected
from various hospitals in France and USA (French Kidney Tumour
Consortium and Cooperative Human Tissue Network). All patients
are of Caucasian origin. This included two patients with bilateral
chromophobe RCC but without evidence of genetic predisposition.
This study was performed after approval from our local Ethics
Committee. Informed consent was obtained from each patient.
Genomic DNA was extracted using the QIAamp DNA Mini Kit
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s(Qiagen, Courtaboeuf, France) according to the manufacturer’s
instructions.
Sequencing analysis
The entire coding region of BHD, TP53, and HNF1b was screened
for mutations by direct sequencing (Nickerson et al, 2002; B.
Bressac-de Paillerets, unpublished data; Rebouissou et al, 2005; see
Supplementary Information).
SNP analysis
Intronic and exonic SNPs (iSNPs and eSNPs) were obtained from
the sequencing results. Rare homozygous genotypes have the
lowest allelic frequencies according to the Hardy–Weinberg’s law.
We used the allelic frequencies of HapMap–CEU (http://
www.hapmap.org).
Methylation analysis of the BHD promoter region
Genomic DNA were incubated with or without HpaII (Invitrogen,
Cergy-Pontoise, France). Polymerase chain reaction (PCR) was
then performed with specific primers (available on request) and
products were analysed on standard agarose gels. The presence of
methylated cytosines was determined by comparing the same
sample under the digested or nondigested conditions, that is, if
cytosines were methylated, HpaII would not be cleaved at the
restriction enzyme sites, and PCR amplification would be
successful.
Statistical analysis
w
2 test was used to compare the mutation frequencies as well as the
frequencies of rare homozygous genotypes of each polymorphism
in each tumour subtype. When the conditions of application of w
2
could not be obtained, a Yates’s correction was applied, or the
Fisher’s exact test was used. Statistical significance was indicated
by Po0.05.
RESULTS AND DISCUSSION
Alterations in BHD
Two nonsense, three frameshift, and three predicted splice
mutations were identified in six samples, five of 46 chromophobe
RCC (10.9%) and one of 18 oncocytomas (5.6%) (Table 1). This is
the first report of somatic BHD mutations in sporadic chromo-
phobe RCC and renal oncocytoma. T16 and T35 exhibited their
respective mutations in both tumour and corresponding matched
normal tissue, showing possible germline mutations, although
contamination of tumour cells in the normal tissue could not be
ruled out completely. Unfortunately, the blood DNA of these
patients could not be obtained to verify their germline mutation
status. T16 also showed loss of the wild-type allele but retained
mutant strand in its tumour tissue (LOH) (Figure 1A). Two
chromophobe RCC (T68 and T87b) showed a double mutation in
each of the tumours. In patient A (T87a and T87b), we detected
two novel somatic mutations and a previously described germline
alteration (Schmidt et al, 2005), which was confirmed with the
patient’s blood DNA. Although patient A did not show any
evidence of genetic predisposition, he has bilateral chromophobe
RCC, and a germline mutation makes him a potential hereditary
case and was referred to genetic counsellors. T68 showed two
distinct somatic mutations not found in the matched normal
tissues. The second somatic mutation is a possible second hit,
instead of LOH, further supporting the tumour suppressive role of
BHD. We did not detect any mutation at the hot spot within exon
11 as reported in BHD patients. The BHD mutation frequency in
chromophobe is statistically not significant compared to the other
subtypes (P40.20, with Yates’s correction). Methylation status of
the BHD promoter was analysed on 61 of 92 samples (39
chromophobe, seven clear cell, and 15 oncocytoma), which had
Table 1 Description of mutations detected in BHD and TP53 genes in 92 sporadic renal tumours
Gene Sample Cell type Exon Mutation description Mutation type Mutated protein Mutation origin
BHD T16 Chromophobe RCC 4 c.103_125(558_580)del23 Frameshift p.Asn35fs Possible germline
T35 Chromophobe RCC 9 c.919(1374)G4T
a Nonsense p.Glu307X Possible germline
T87a Chromophobe RCC 9 c.995_998(1450_1453)del4 Frameshift p.Leu332fs Somatic
T87b Chromophobe RCC 9 c.1062(IVS9)+2T4G Predicted splice mutation x Germline
T87b Chromophobe RCC 11 c.1179(1634)delC Frameshift p.Thr393fs Somatic
T68 Chromophobe RCC 11 c.1177(IVS10)-6delCCT Predicted splice mutation x Somatic
T68 Chromophobe RCC 13 c.1433(IVS12)-2A4T Predicted splice mutation x Somatic
T55 Oncocytoma 14 c.1659(2114)G4A Nonsense p.Trp553X Somatic
TP53 T70 Chromophobe RCC 4 c.150_157del8
b Frameshift p.Ile50fs ND
T75 Chromophobe RCC 4 c.375G4A
c Predicted splice mutation p.Thr125Thr ND
T72 Chromophobe RCC 5 c.393_395delCAA In frame deletion p.Asn131del Somatic
T41 Chromophobe RCC 5 c.469G4T Missense p.Val157Phe Somatic
T66 Chromophobe RCC 6 c.569delC Frameshift p.Pro190fs Somatic
T34 Chromophobe RCC 6 c.644G4T Missense p.Ser215Ile Somatic
T33 Chromophobe RCC 7 c.757A4G Missense p.Thr253Ala Somatic
T43 Chromophobe RCC 8 c.817C4T Missense p.Arg273Cys Somatic
T63 Chromophobe RCC 8 c.832C4A Missense p.Pro278Thr ND
T45 Chromophobe RCC 8 c.877dupA Frameshift p.Gly293fs ND
T62 Chromophobe RCC 10 c.1009C4T Missense p.Arg337Cys ND
T9 Clear cell RCC 5 c.467G4A Missense p.Arg156His Possible germline
T26 Papillary RCC 8 c.832C4A Missense p.Pro278Thr Somatic
Abbreviations: BHD¼Birt–Hogg–Dube ´;N D¼Not determined owing to the unavailability of matched normal tissue.
aFor BHD, c. corresponds to coding sequence relative to
ATG in exon 4 (Genbank accession number NM_144997). Numbers in brackets are refering to the previous nomenclature used (Genbank accession number AF517523).
bFor
TP53, c. corresponds to coding sequence according to ATG in exon 2 (Genbank accession number NM_000546).
cNot a silent mutation because it involves the last base of exon
4 and has been reported to be responsible for exon skipping.
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evidence of BHD promoter methylation was found.
Mutations in TP53
Eight missense, three frameshift, one in-frame, and one predicted
splice mutations were identified in 13 tumours, 11 of 46
chromophobe (23.9%), one of 19 clear cell (5.3%), and one of
nine papillary RCC (11.1%). The mutation in T75 is located at the
last base of exon 4 that can induce a splicing effect (Holmila et al,
2003). A known hot spot mutation in sarcomatoid RCC (Oda et al,
1995) has been detected in one papillary (T26) and one
chromophobe (T63). A sarcomatoid component can occur in all
subtypes, and its presence indicates poor outcome (Cheville et al,
2004). The matched normal tissue of T9, a clear cell subtype, has
the same mutation as its tumour tissue, suggesting a possible
germline mutation (Figure 1B). However, no blood DNA was
available to confirm its germline status. All TP53 muta-
tions detected here have been described in the TP53 database
(www-p53.iarc.fr/P53aim.html). The TP53 mutation frequency in
chromophobe is statistically significant compared to the other
subtypes (Po0.01). Therefore, TP53 mutations occur preferentially
in chromophobe as reported (Contractor et al, 1997). The high
percentage of TP53 mutations in chromophobe could reflect the
different pathways in its tumorigenesis, compared to other
subtypes.
Analysis of HNF1b
No mutations were identified in all coding exons of the HNF1b
gene. However, an insertion of a cytosine in the intron 8 was
detected (Table 2, and Table 3 in Supplementary Information).
This is a deletion/insertion polymorphism (DIP) that has been
reported previously (Horikawa et al, 1997). Here the frequency of
its rare genotype (insC) in chromophobe is statistically significant
compared to the other subtypes (Po0.02). Furthermore, this
variant was observed in a normal tissue sample, but was lost in the
matched tumour through LOH (Figure 1C). We could not establish
any relationship between HNF1b and sporadic RCC as we did not
find any mutations, suggesting HNF1b mutation as a very rare
genetic event in sporadic renal tumours.
Analysis of SNPs in BHD, TP53, and HNF1b
We detected 14 SNPs, including one possible new iSNP in BHD
(Table 2 and Supplementary Table 3). All tumours that carry the
BHD mutations showed homozygosity in all four iSNPs. All except
two TP53-mutated tumours (T26 and T45) demonstrated homo-
zygous alleles in all four SNPs. In addition, the proportion of
samples showing homozygous SNP alleles in BHD, TP53, and
HNF1b are 41/92 (44.6%), 65/92 (70.6%), and 37/92 (40.2%),
respectively. Chromophobe RCC exhibited the highest percentage
of rare homozygous genotypes (Table 2). Among the 92 renal
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Figure 1 Sequence chromatograms for BHD, TP53, and HNF1b. R, N, and T are DNA from a commercially available reference, the normal tissue and its
matched tumour tissue, respectively. (A) Corresponds to BHD with a somatic mutation (T68, c.1433(IVS12)-2A4T) (left) and a possible germline mutation
(T16, c.103_125(558_580)del23) (right). (B) Corresponds to TP53 with a somatic mutation (T72, c.393_395delCAA) (left) and a possible germline
mutation (T9, c.467G4A) (right). (C) Corresponds to HNF1b with a cytosine insertion in intron 8 (left) and a SNP in the non-coding region of exon 9
(c.*99C4) (right).
BHD and TP53 mutations in chromophobe RCC
S Gad et al
338
British Journal of Cancer (2007) 96(2), 336–340 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
stumours, 24 samples are homozygous for all SNP studied (26%).
Twenty-one of them are of chromophobe subtype (45.6% of all
chromophobe; Po0.001). One of them carries a BHD mutation and
eight of them have TP53 mutations (72.7% of TP53-mutated
chromophobe; Po0.02). The other three are of oncocytoma
subtype (16.7% of all oncocytoma). Homozygous SNP alleles
detected in this study may indicate chromosomal deletions. In
samples with mutations, it may suggest LOH, which is consistent
with the two-hit hypothesis. However, we also noticed the high
frequency of homozygous SNP alleles especially in samples without
TP53 mutation (70%). Although it has been shown that p53 is
functional in p53 wild-type RCC cells (Warburton et al, 2005), the
relationship between chromosomal 17 deletions and TP53,
especially in sporadic chromophobe subtype, is worth further
investigation.
In summary, BHD and TP53 may play an important role as
tumour suppressors in chromophobe RCC.
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